Pharmacovigilance Market Growth & Trends
The global pharmacovigilance market size is expected to reach USD 17.36 billion by 2030, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.3% from 2023 to 2030. The increasing incidence of Adverse Drug Reactions (ADR) is a key growth factor. ADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.
COVID-19 has undoubtedly thrown up numerous challenges as well as opportunities for pharmacovigilance service providers. Various companies are developing innovative platforms to gain a competitive edge. For instance, in December 2020, ArisGlobal and EVERSANA declared a strategic partnership to digitally transform end-to-end pharmacovigilance services globally.
The community involved in PV procedure has been quick to respond to the pandemic. Some companies are using big data analytics against COVID-19. Thus, this refers to a depth analysis of data from multiple sources. In April 2020, Saama Technologies offered its Life Science Analytics Cloud technology platform to support the consortium creation. The purpose is to fetch data from both current and future studies to slash the time required to discover a treatment by as much as 50%. Life Science Analytics Cloud is an artificial intelligence-powered platform. This represents the scope for future developments in this market.
According to the World Health Organization's (WHO) report on pharmaceutical consumption, chronic disease medications accounted for a larger proportion of the total volume of drug consumption in non-hospital setups. Hence, there has been a significant rise in the number of medicines made available to healthcare consumers. The rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.
Moreover, leading pharma companies in developed countries are focusing on outsourcing PV services to reduce costs and minimize operational expenses. This is anticipated to provide an opportunity to contact research organizations in developing regions to gain more revenue share. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.
The companies operating in the market are undertaking strategic initiatives, such as collaborations with PV service providers to gain access to medical information and manage PV workflows. For instance, In October 2021, The Whiteboard, an academy for training specialists in the clinical trials and drug development field, proclaimed a partnership with OviyaMedSafe, a worldwide drug safety service and pharmacovigilance consulting corporation.
Similarly, in September 2019, Accenture collaborated with Bayer to implement the company's INTIENT Clinical platform to simplify and speed up its drug development processes, thereby widening its business. The company collaborated with BioCelebrate in the past to develop a platform for aggregating and analyzing clinical information for improving the efficiency of drug development, thus enhancing its R&D capabilities. Such initiatives help companies maintain their position and thereby support the market growth.
Request a free sample copy or view report summary: Pharmacovigilance Market Report
Pharmacovigilance Market Report Highlights
By product life cycle, phase IV held a dominant share of over 75.8% in 2022 owing to the extensive post-marketing surveillance of pharmaceuticals and an increasing number of ADR incidences in the market
By service provider, contract outsourcing held a significant share of over 60.0% in 2022 owing to the shift in the focus of pharmaceutical companies toward outsourcing services to reduce operational cost
Based on type, spontaneous reporting held the largest revenue share in 2022 due to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison
The biotechnology companies end-use segment is anticipated to exhibit a lucrative CAGR over the forecast period owing to increasing R&D for the development of novel biologics
Asia Pacific is anticipated to register a lucrative CAGR of 10.8% over the forecast period. This is attributed to the availability of low-cost labor and the rising number of outsourcing companies in this region
Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services. Moreover, companies are adopting strategies including new product launches, collaborations, and mergers & acquisitions to gain a competitive advantage
Access Press Release@ https://www.grandviewresearch.com/press-release/global-pharmacovigilance-market
Pharmacovigilance Market Segmentation
Grand View Research has segmented the global pharmacovigilance market on the basis of product life cycle, service provider, type, process flow, therapeutic area, end-use, and region:
Pharmacovigilance Product Life Cycle Outlook (Revenue, USD Million, 2017 - 2030)
Pre-clinical
Phase I
Phase II
Phase III
Phase IV
Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2017 - 2030)
In-house
Contract Outsourcing
Pharmacovigilance Type Outlook (Revenue, USD Million, 2017 - 2030)
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Pharmacovigilance Process Flow Outlook (Revenue, USD Million, 2017 - 2030)
Case Data Management
Case Logging
Case Data Analysis
Medical Reviewing & Reporting
Signal Detection
Adverse Event Logging
Adverse Event Analysis
Adverse Event Review & Reporting
Risk Management System
Risk Evaluation System
Risk Mitigation System
Pharmacovigilance Therapeutic Area Outlook (Revenue, USD Million, 2017 - 2030)
Oncology
Neurology
Cardiology
Respiratory Systems
Others
Pharmacovigilance End-use Outlook (Revenue, USD Million, 2017 - 2030)
Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others
Pharmacovigilance Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
MEA
South Africa
Kingdom of Saudi Arabia
List of Key Players of Pharmacovigilance Market
Accenture
Clinquest Group B.V. (Linical Americas)
IQVIA
Cognizant
Laboratory Corporation of America Holdings
IBM Corporation
ArisGlobal
ICON Plc.
Capgemini
ITClinical
TAKE Solutions
PAREXEL International Corporation
BioClinica, Inc.
Wipro Limited
UNITED BIOSOURCE CORPORATION
FMD K&L
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment